Tiziana Life Sciences Founder and Executive Chairman Gabriele Cerrone purchased 42,357 additional common shares at $0.99 per share.
The transaction, executed through Panetta Partners Ltd., brings Cerrone’s total holdings to 44,814,587 shares. This position represents 34.93% of the company's total issued share capital.
The purchase signals confidence in Tiziana’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. This increased ownership supports the development of the company's immunomodulation platform for neuroinflammatory and neurodegenerative diseases.